Stock_Titan Posted - 17 hours ago

$CTKB Cytek Biosciences Reports First Quarter 2024 Financial Results https://www.stocktitan.net/news/CTKB/cytek-biosciences-reports-first-quarter-2024-financial-3o39frzsrr2r.html

StockInvest_us Posted - 1 week ago

Signal alert: $CTKB - PivotPoint bottom https://stockinvest.us/l/x2F21fjlE7

Stock_Titan Posted - 04/30/24

$CTKB Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe https://www.stocktitan.net/news/CTKB/cytek-r-biosciences-to-spotlight-cell-analysis-solutions-at-upcoming-i7o40xcrbv25.html

Stock_Titan Posted - 04/29/24

$CTKB Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024 https://www.stocktitan.net/news/CTKB/cytek-biosciences-to-report-first-quarter-2024-financial-results-on-kfob7em544te.html

insiderbuyingselling Posted - 04/23/24

$CTKB new insider selling: 20000 shares. http://insiderbuyingselling.com/?t=CTKB

insiderbuyingselling Posted - 04/11/24

$CTKB new insider selling: 1900 shares. http://insiderbuyingselling.com/?t=CTKB

Stock_Titan Posted - 03/19/24

$CTKB Cytek® Biosciences Names William McCombe Chief Financial Officer https://www.stocktitan.net/news/CTKB/cytek-r-biosciences-names-william-mc-combe-chief-financial-baiaewypq5cf.html

DailyStocksPicks Posted - 03/17/24

EyePoint Pharmaceuticals Inc. ($EYPT) appears undervalued after outperforming fourth-quarter earnings expectations and showing promising clinical trial results for EYP-1901. Despite a bearish sentiment due to revised revenue forecasts, the company's financial health and positive clinical outcomes suggest a potential market correction, making it a compelling consideration for investors looking for long-term value. $PACB, $QTRX, $CTKB, $LAB For More Details https://youtu.be/53IHP3Y7EFc

DonCorleone77 Posted - 2 months ago

$CTKB Cytek Biosciences opens new 50,000-square-foot facility in China Cytek Biosciences announced that it has opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company's manufacturing capacity to meet the demand for cell analysis solutions. The Wuxi facility offers vendor relationships and further facilitates Cytek to manufacture its own components. In addition to bolstering Cytek's manufacturing capabilities, the facility also accommodates Cytek Wuxi operations, research and development, marketing, human resources, and sales teams.

Kevin73ca Posted - 2 months ago

$CTKB opens 50k square facility in China Watch

Stock_Titan Posted - 2 months ago

$CTKB Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions https://www.stocktitan.net/news/CTKB/cytek-r-biosciences-opens-new-facility-to-address-increasing-global-kbdqhx3vcp2l.html

DailyStocksPicks Posted - 2 months ago

Today’s pick number one is $CTKB. Cytek Biosciences Inc., a company that specializes in cell analysis solutions. Cytek has developed a cutting-edge technology known as Full Spectrum Profiling. Based in Fremont, California, it operates within the Medical - Biomedical and Genetics industry, which is ranked number 74 out of 252 by Zacks. Despite showcasing strong financial results and a positive outlook for FY 2024, CTKB might be considered oversold due to market reactions not fully reflecting its financial health and growth potential. This discrepancy could stem from broader market trends overshadowing the company's solid performance and future prospects. $EYPT, $QTRX, $PACB, $ALLO For more details https://youtu.be/cSfffj0OIas

DonCorleone77 Posted - 02/28/24

$CTKB Cytek Biosciences sees FY24 revenue $203M-$213M, consensus $207.1M

DonCorleone77 Posted - 02/28/24

$CTKB Cytek Biosciences reports Q4 adjusted EBITDA $11.0M vs. $6.6M last year Reports Q4 revenue $58.6M, consensus $56.6M. "We delivered strong fourth quarter performance amidst a challenging macro-economic environment. Our teams navigated well while executing our business strategy, and we took actions to ensure that we remain an agile organization," said Dr. Wenbin Jiang, CEO of Cytek Bioscience. "As we look ahead to 2024, we remain laser focused on effectively driving strategic growth and delivering long-term profitability. Cytek remains on the forefront of innovation and industry leadership, and we are excited for the large opportunities ahead."

Stock_Titan Posted - 02/28/24

$CTKB Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook https://www.stocktitan.net/news/CTKB/cytek-biosciences-reports-fourth-quarter-and-full-year-2023-7re7uzh8x3t2.html

swingingtech Posted - 02/21/24

$CTKB https://wallstreetwaves.com/commit-to-purchase-cytek-biosciences-at-7-50-earn-33-6-annualized-using-options/

Stock_Titan Posted - 3 months ago

$CTKB Cytek Biosciences to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/CTKB/cytek-biosciences-to-participate-in-upcoming-investor-4q7vzijxnqsb.html

Stock_Titan Posted - 3 months ago

$CTKB Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 https://www.stocktitan.net/news/CTKB/cytek-biosciences-to-report-fourth-quarter-and-full-year-2023-ci8ytisk8u4d.html

DailyStocksPicks Posted - 01/31/24

My Oversold Stock Pick #4 Today: Cytek Biosciences, Inc. specializes in advanced cell analysis solutions. The perception of Cytek Biosciences, Inc. ($CTKB) as being oversold may stem from recent positive developments, such as the announcement of preliminary, unaudited revenue results for 2023 expected to be at the high end of their guidance range, strategic collaborations to accelerate scientific discoveries, and a $50 million stock repurchase program. These factors, indicative of the company's financial health and growth potential, could have led to expectations of stock appreciation. However, the market's immediate reaction or broader market trends might not fully reflect these positive aspects, contributing to the view that the stock is oversold​​​​​​. For more details https://youtu.be/IUUHEg1uJbQ

StockAutomatePro Posted - 01/24/24

$CTKB Chart is suggesting a bright future for the stock price. We alerted the BUY signal at $8.1 and we were able to close this one with profit at $8.76🤙 See more details at StockAutomate.com

cctranscripts Posted - 01/23/24

BlackRock, Inc. just provided an update on share ownership of Cytek Biosciences, Inc. https://www.conferencecalltranscripts.org/summary/?id=12887991 $CTKB

STCKPRO Posted - 01/18/24

$CTKB NEW ARTICLE : Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries https://stck.pro/news/CTKB/73000702/

DonCorleone77 Posted - 01/17/24

$CTKB Cytek Biosciences signs agreement with CRG, UPF to accelerate discoveries Cytek Biosciences has signed an agreement with the Centre for Genomic Regulation, or CRG, and the Pompeu Fabra University, or UPF, to drive technological innovation and accelerate discoveries for the scientific community. Under the terms of the agreement, Cytek will provide new spectral cytometry platforms - along with trained support personnel - to the CRG-UPF Flow Cytometry Unit's headquarters. The Unit, founded in 2001 and based in the Barcelona Biomedical Research Park, is a worldwide reference site for advanced flow cytometry applications.

Last10K Posted - 4 months ago

$CTKB just filed with the SEC a Earnings Release and a Financial Exhibit https://last10k.com/sec-filings/CTKB/0001193125-24-004805.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=CTKB

cctranscripts Posted - 4 months ago

Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results FREMONT, Calif., January https://www.conferencecalltranscripts.org/summary/?id=12852930 $CTKB

risenhoover Posted - 4 months ago

$CTKB / Cytek Biosciences files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Cytek Biosciences https://fintel.io/doc/sec-cytek-biosciences-inc-1831915-8k-2024-january-09-19731-418?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

EarningsInsider Posted - 4 months ago

$CTKB updates FY 2023 guidance to EPS and revenue guidance to $192.0 million-$192.0 million. www.marketbeat.com/stocks/NASDAQ/CTKB/earnings

Stock_Titan Posted - 4 months ago

$CTKB Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results https://www.stocktitan.net/news/CTKB/cytek-biosciences-announces-preliminary-full-year-2023-revenue-24wlrtuzwskw.html

MargoRichardson Posted - 4 months ago

$RPD $WEAT $CTKB $WEN ACCOUNT CHALLENGE UPDATE: Starting Balance: $3,700 Current Balance: $54,873 Goal: $100K by end of Jan. Watch out for our next alert<.>💖 top-stocks-winning-great-us.blogspot.com/2023/11/blog-post.html